Previous 10 | Next 10 |
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo...
Gevo (NASDAQ: GEVO ) +45% on supplying its sustainable and renewable alcohol-to-jet fuel to Avfuel. More news on: Gevo, Inc., Bank OZK, V.F. Corporation, Stocks on the move, , Read more ...
REDWOOD CITY, Calif. , Jan. 7, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the...
CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden...
REDWOOD CITY, Calif. , Nov. 7, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management w...
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Gilead Sciences Makes Another Push Towards Immuno-Oncology News: Recently, Gilead Sciences ( GILD ) announced that it had formed a collaboration wi...
AcelRx Pharmaceuticals, Inc. (ACRX) DSUVIA FDA Approval and AcelRx Third Quarter 2018 Conference Call November 05, 2018 08:30 AM ET Executives John Saia - General Counsel Vince Angotti - CEO Dr. Pam Palmer - Chief Medical Officer Kimberley Gaumer - VP, Regulatory Affairs and Qu...
In the early afternoon on Friday, November 2, AcelRx's (NASDAQ: ACRX ) shares were halted by NASDAQ pending news from the company. Around an hour later, ACRX released a press release announcing that the company's lead drug candidate Dsuvia had been approved by the FDA for the treatment of a...
CORAL GABLES, FL / ACCESSWIRE / November 5, 2018 / It's no secret that technology has facilitated access and directly helped meet consumer needs in a multitude of industries. Healthcare has become the latest market to take full advantage of this trend. With the advent of technology in he...
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / AcelRx Pharmaceuticals saw big gains this past Friday after announcing third quarter results and an update on DSUVIA receiving FDA approval. Shares of Sage Therapeutics were halted after its treatment Zulresso, was recommended by an FDA approval...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...